Xingzhi Bio

Based in Suzhou, China and founded in 2019, Xingzhi Bio operates as a liquid biopsy medical technology developer, focusing on the development of precision medical liquid biopsy related technology. The company was founded by Professor Wenchu Lin, an expert from the Chinese Academy of Sciences. Xingzhi Bio has established a research and development center in Suzhou, and a GMP factory, a medical device production workshop in Hefei.Konimex has strategic cooperation with the company. The services and products provided by the company include primer and probe design services, molecular biology reagent supply services and automated nucleic acid extractors. The company can provide a wide range of primers and can also synthesize a variety of base modified primers, marker primers and fluorescent marker primers, which can be used in various experiments, such as PCR, fluorescent quantitative PCR, first-generation sequencing, and second-generation sequencing. Automatic nucleic acid extractor and corresponding magnetic bead method nucleic acid extraction reagents can extract DNA and RNA from samples of animal and plant tissues, blood, body fluids, food, pathogenic microorganisms, which can be used for nucleic acid extraction and purification of biological samples, and are suitable for clinical testing, routine scientific research, genomics analysis, disease control systems, food safety inspection, forensic identification and other fields.

1. Series A

   Oct 22, 2022

   Amount

   Undisclosed

   Investors

   Locked

2. Angel

   Jan 31, 2020

   Amount

   $0.7M

   Investors

   Locked